MA39072A1 - Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales - Google Patents

Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Info

Publication number
MA39072A1
MA39072A1 MA39072A MA39072A MA39072A1 MA 39072 A1 MA39072 A1 MA 39072A1 MA 39072 A MA39072 A MA 39072A MA 39072 A MA39072 A MA 39072A MA 39072 A1 MA39072 A1 MA 39072A1
Authority
MA
Morocco
Prior art keywords
pelvic
antagonists
prevention
treatment
par
Prior art date
Application number
MA39072A
Other languages
English (en)
Inventor
Grand Bruno Le
Didier Junquero
Nicolas Monjotin
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA39072A1 publication Critical patent/MA39072A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne l'utilisation de par1 antagonistes, notamment du vorapaxar, de l'atopaxar et de la 3-(2-chloro-phényl)-1-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propénone ou l'un de leurs sels pharmaceutiquement acceptables pour la prévention et/ou le traitement des pathologies fonctionnelles pelvi-périnéales, et plus particulièrement du syndrome douloureux vésical.
MA39072A 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales MA39072A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1362682A FR3014693B1 (fr) 2013-12-16 2013-12-16 Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
PCT/EP2014/073453 WO2015090705A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Publications (1)

Publication Number Publication Date
MA39072A1 true MA39072A1 (fr) 2017-05-31

Family

ID=50424483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39072A MA39072A1 (fr) 2013-12-16 2014-10-31 Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales

Country Status (17)

Country Link
US (2) US9980970B2 (fr)
EP (1) EP3082818A1 (fr)
JP (1) JP6612233B2 (fr)
KR (1) KR20160089518A (fr)
CN (1) CN105813642B (fr)
AU (1) AU2014365665B2 (fr)
CA (1) CA2931161A1 (fr)
FR (1) FR3014693B1 (fr)
HK (1) HK1221913A1 (fr)
IL (1) IL246216A0 (fr)
MA (1) MA39072A1 (fr)
MX (1) MX370061B (fr)
RU (1) RU2678309C1 (fr)
SA (1) SA516371348B1 (fr)
TN (1) TN2016000196A1 (fr)
UA (1) UA120603C2 (fr)
WO (1) WO2015090705A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3090317B1 (fr) * 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110393718B (zh) * 2019-08-20 2022-10-04 青岛海洋生物医药研究院 阿托帕沙溴酸作为新型jak-stat3信号通路抑制剂的用途和研究方法
FR3109089B1 (fr) * 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482858C (fr) 2002-04-16 2010-11-30 Schering Corporation Antagonistes tricycliques du recepteur de thrombine
CA2586344C (fr) * 2004-11-04 2013-05-28 New England Medical Center Hospitals, Inc. Agonistes et antagonistes de recepteurs couples aux proteines g et methodes d'utilisation
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
US20140378502A1 (en) * 2011-05-12 2014-12-25 UNIVERSITé LAVAL Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections
RU2468759C1 (ru) * 2011-09-23 2012-12-10 Ольга Викторовна Тарабанова Способ лечения нарушений анатомических соотношений органов малого таза у женщин с атрофией мышц, поднимающих задний проход, и/или множественными дефектами ректо-вагинальной фасции

Also Published As

Publication number Publication date
UA120603C2 (uk) 2020-01-10
US20160287603A1 (en) 2016-10-06
US9980970B2 (en) 2018-05-29
US10265322B2 (en) 2019-04-23
SA516371348B1 (ar) 2019-11-10
CA2931161A1 (fr) 2015-06-25
FR3014693A1 (fr) 2015-06-19
JP6612233B2 (ja) 2019-11-27
FR3014693B1 (fr) 2016-01-08
MX2016007795A (es) 2016-09-07
AU2014365665A1 (en) 2016-07-14
US20180311253A1 (en) 2018-11-01
IL246216A0 (en) 2016-07-31
CN105813642A (zh) 2016-07-27
KR20160089518A (ko) 2016-07-27
WO2015090705A1 (fr) 2015-06-25
MX370061B (es) 2019-11-29
HK1221913A1 (zh) 2017-06-16
CN105813642B (zh) 2019-05-03
RU2678309C1 (ru) 2019-01-25
EP3082818A1 (fr) 2016-10-26
AU2014365665B2 (en) 2019-08-29
JP2016540799A (ja) 2016-12-28
TN2016000196A1 (fr) 2017-10-06

Similar Documents

Publication Publication Date Title
EA201500362A1 (ru) Ингибиторы rho-киназы
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
MX2016000646A (es) Sulfonamidas como moduladores de canales de sodio.
TR201901886T4 (tr) DNA-PK inhibitörleri.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX2015017964A (es) Inhibidores de bromodominio.
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201690872A3 (ru) Противовирусная терапия
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
EA201290860A1 (ru) Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
MA35638B1 (fr) 2-thiopyrimidinones
PH12015502365A1 (en) Bace1 inhibitors
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
TR201911232T4 (tr) Otoimmünite gelişimine yönelik coriolus versicolorun ekstraktını içeren topikal bileşimler.
MA39072A1 (fr) Utilisation d'antagonistes par-1 pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора
EA202190428A1 (ru) Антагонисты интегрина
TH167368B (th) การใช้ของ par-1 แอนทาโกนิสต์ สำหรับการป้องกันและ/หรือการบำบัดสภาวะ ทางพยาธิวิทยาเชิงการทำหน้าที่ของอุ้งเชิงกราน-ฝีเย็บ
TN2015000431A1 (en) Use of pidotimod to treat irritable bowel syndrome
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées